[1] INTERNATIONAL AGENCY FOR RESEARCH ON CANCER. Latest global cancer data: cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in2020[EB/OL](2020-12-15)[2025-06-01].https://www.iarc.who.int/news-events/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020/.
[2] CHIDAMBARANATHAN-REGHUPATY S, FISHER P B, SARKAR D.Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification[J]. Adv Cancer Res, 2021, 149: 1-61.
[3] 樊蓉,陈磊,杜鲁涛,等.中国肝癌早筛策略专家共识[J].肝癌, 2021, 26(8): 825-831.
[4] 孙嘉阳,胡威,唐玉.全球肝癌新药研发临床试验进展总结[J/CD]. 肝癌电子杂志, 2024, 11(4): 1-5.
[5] FINN R S, IKEDA M, ZHU A X, et al. Phase Ⅰb study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(26): JCO.20.00808.
[6] KUDO M, UESHIMA K, SAEKI I, et al.A Phase 2, prospective, multicenter, single-arm trial of transarterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable intermediate-stage hepatocellular carcinoma: TACTICS-L trial[J]. Liver Cancer, 2023, 13(1): 99-112.
[7] PENG Z, FAN W, ZHU B, et al.Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase Ⅲ, randomized clinical trial (LAUNCH)[J]. J Clin Oncol, 2023, 41(1): 117-127.
[8] ZHANG W, TONG S, HU B, et al.Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase Ⅱ trial[J]. J ImmunoTher Cancer, 2023, 11(9): e007366.
[9] 国家卫生健康委员会办公厅关于印发卫生健康行业人工智能应用场景参考指引的通知[EB/OL].(2024-11-06)[2025-01-09].http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=647062ee76764323b29a1f0124b64400. |
